CTI BioPharma has obtained Israeli Ministry of Health’s approval for Pixuvri (pixantrone), as a monotherapy to treat adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma who have received up to three previous courses of treatment.

The company also announced that the Dutch Healthcare Authority and the College voor zorgverzekeringen of the Netherlands have approved funding for Pixuvri as an add-on drug for patients who need a third or fourth-line treatment option for aggressive B-cell lymphoma.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Tel Aviv University faculty of medicine Dr Abraham Avigdor said: "The approval of PIXUVRI in Israel provides patients with aggressive B-cell NHL who have failed second or third-line therapy a new approved option, where none existed before, that can effectively treat their disease with manageable side-effects.

"It is vital to have additional treatment options available, like Pixuvri, so we can provide these patients the best care possible and help them battle their disease."

"Patients who have relapsed after second-line therapy have a poor survival outcome.

"It is vital to have additional treatment options available, like Pixuvri, so we can provide these patients the best care possible and help them battle their disease."

See Also:

CTI BioPharma said that the benefit of pixantrone treatment has not been established in patients when used as fifth line or greater chemotherapy in patients who are refractory to last therapy.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Neopharm will distribute and market Pixuvri, an aza-anthracenedione, in Israel once the drug is included in the Israeli National Health Basket of drugs by the Ministry of Health.

Pixuvri was approved by the European Commission in May 2012 as a monotherapy for treatment of adult patients with relapsed or refractory aggressive B-cell NHL.